iPSC-ing into the future of cell therapy: expansion in a hollow-fiber bioreactor

Induced pluripotent stem cell (iPSC)-derived therapies have opened up a new avenue for stem cell research and unique opportunities to shift cell therapy into an allogeneic paradigm. The development of these therapies requires high-quality iPSC banks generated via standardized workflows to minimize starting material bank-to-bank variability.

Two expert scientists will share their long-standing experience working with IPSCs, the associated challenges, and the workflow and protocol optimizations needed to achieve doses relevant for clinical studies or further manufacturing.

They will explain how to move from manual processes to a functionally closed, automated, and scalable system effectively using hollow-fiber perfusion technology to expand iPSCs.

In this webinar you will learn more about:

• Providing a consistent and tailored environment for iPSC expansion by hollow-fiber perfusion technology
• How to increase GMP compliance and process standardization
• How to close the seed train by scaling down on this automated platform
• How to scale up and out to manufacture high-quality iPSC banks

Nathan Frank

Laboratory Scientist IV at Terumo Blood and Cell Technologies

Nate has more than a decade of experience optimizing parameters for cell and gene therapy production and scale-up. He has specialized expertise in hollow-fiber bioreactor process development for a range of cell types aimed at various applications in regenerative medicine and immunotherapy. He is a two-time National Science Foundation fellow and has a passion for teaching and communicating science to a wide range of audiences from established professionals to middle and high school students who are just beginning their scientific journey.

Molly Tregidgo

Associate Senior Scientist - Technology, Process & Innovation, Cell & Gene Therapy at Catapult

Molly Tregidgo obtained her degree in Biochemical Engineering from University College London in 2015, where she later completed her EngD investigating novel scale-down models for perfusion bioprocess development. She joined Cell and Gene Therapy Catapult (CGTC) in 2021, as a Bioprocessing Scientist.

At CGTC she works in Upstream Bioprocessing with allogeneic cell therapies across a range of bioreactor platforms, specialising in scale-up/down of cell culture processes.

Watch now

SPEAKERS

Nathan Frank

Laboratory Scientist IV at Terumo Blood and Cell Technologies

Molly Tregidgo

Associate Senior Scientist - Technology, Process & Innovation, Cell & Gene Therapy at Catapult

You might also like

iPSC-based therapy dilemmas explored: overcoming hurdles for future success

L Munsie, K Raineri, M Carpenter et al.

5 March

Watch

iPSC cell line development and manufacture for cell therapies

R Flynn, B Ressler, D Hei et al.

14 March

Watch

Improving cell therapy manufacturing with on-line monitoring of critical process parameters during cell expansion

Boris Aleynik, Mindy Miller

16 July

Watch

Preventing cross-contamination in cell therapy production

Josh Ludwig, Mary Kay Bates

1 October

Watch

Improving AAV productivity: a technical deep-dive into next-generation solutions for cell and gene therapy applications

Jim Ludtke, Fletcher Malcom

5 December

in 14

Days

Register